About Us

A Differentiated Approach to Target and Drug Discovery

At Invea, we use a proprietary AI platform to expedite the discovery and development of precision medicines for gastrointestinal and hepatobiliary disorders impacted by dysregulation of the GBA. We have focused our attention on applying AI and machine learning as a force multiplier to aid in target and drug discovery, disease indication prioritization, through to successful clinical development and approval.

Our differentiated approach

We were spun out by InveniAI, our parent, in 2021 and are headquartered in Guilford, Connecticut.

Meet our team

We leverage an executive team and board of directors and advisors with a track record of creating lasting impact in healthcare innovation.

© 2022 Invea Therapeutics, Inc. All rights reserved